Harmony Biosciences sets terms on $100M IPO; FDA accepts a Protalix BLA for review
Paragon portfolio company Harmony Biosciences announced its IPO terms on Tuesday, which set a range of $20 and $23 a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.